Herein, we also discuss emerging evidence on CHM’s benefits in IgA nephropathy, including reduced proteinuria and inflammation, and its potential synergy with conventional treatments such as angiotensin-converting enzyme (ACE) inhibitors. This evidence concerns the gene CHM and IgA glomerulonephritis.